X-Square Capital Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$3.04M |
| 2 |
Mercado Libre
MELI
|
+$2.12M |
| 3 |
Popular Inc
BPOP
|
+$2.09M |
| 4 |
iShares Bitcoin Trust
IBIT
|
+$2.07M |
| 5 |
Frontline
FRO
|
+$1.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$2.89M |
| 2 |
Texas Pacific Land
TPL
|
+$2.49M |
| 3 |
First Bancorp
FBP
|
+$1.31M |
| 4 |
RH
RH
|
+$1.05M |
| 5 |
ProShares Ultra Bloomberg Crude Oil
UCO
|
+$902K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.8% |
| 2 | Financials | 15.3% |
| 3 | Miscellaneous | 15.19% |
| 4 | Technology | 12.91% |
| 5 | Industrials | 10.8% |
Similar funds
X-Square Capital's Q4 2024 Portfolio in Review
As of Q4 2024, X-Square Capital held 175 positions worth $243M, up 6.9% from $228M the previous quarter. Its ten largest holdings account for 26% of the portfolio.
X-Square Capital deployed $10.6M of net new capital in Q4 2024, opening 14 new positions and adding to 66 existing holdings. Its largest new stake was Frontline: 88,828 shares worth $1.26M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 16% a quarter earlier, followed by Financials and Miscellaneous.
On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $2.89M trimmed.
- X-Square Capital's largest Q4 2024 buy was Frontline: 88,828 shares worth $1.26M.
- X-Square Capital added most to Tesla in Q4 2024, an estimated $3.04M increase.
- X-Square Capital's biggest Q4 2024 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $2.89M.
- X-Square Capital fully exited ProShares Ultra Bloomberg Crude Oil in Q4 2024, selling an estimated $902K.
- X-Square Capital's ten largest holdings make up 26% of its $243M portfolio in Q4 2024.
- X-Square Capital opened 14 new positions and closed 12 in Q4 2024.
- X-Square Capital's portfolio value rose 6.9% quarter-over-quarter to $243M.
Based on X-Square Capital's 13F filing for Q4 2024, filed 12 Feb 2025.